Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.35 |
| ▸ | CCNC | P24863 | 4/20 | 0.35 |
| ▸ | CDK8 | P49336 | 4/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610790 | 0.85 | KDR (0.38) | KDRCCNCCDK8FFAR2 | |
| SCHEMBL16610821 | 0.85 | KDR (0.38) | KDRCCNCCDK8FFAR2 | |
| SCHEMBL16610758 | 0.84 | KDR (0.40) | KDR | |
| SCHEMBL16610784 | 0.83 | KDR (0.39) | KDRCCNCCDK8FFAR2 | |
| SCHEMBL16610603 | 0.80 | KDR (0.40) | KDR | |
| SCHEMBL16610688 | 0.80 | KDR (0.40) | KDR | |
| SCHEMBL16610501 | 0.77 | KDR (0.38) | KDRCCNCCDK8 | |
| SCHEMBL16610590 | 0.77 | KDR (0.37) | KDR | |
| SCHEMBL16611122 | 0.77 | PDE2A (0.39) | CCNCCDK8PDE2A | |
| SCHEMBL16772698 | 0.76 | KDR (0.36) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | claimed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | claimed |
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2015-06-04 | — | — | US | claimed |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2857398-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | HRH4, CYP3A4, CYP3A5 | KDR 2945/4885CCNC 4579/4885CDK8 4567/4885 |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | ROS1, NOX4, NOX3 | KDR 301/4885CCNC 3648/4885CDK8 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.